PTC Therapeutics Stock News

PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength dow

PTC Therapeutics'' announcement that it expects $700M-$750M in revenue this year is propelling shares higher.

(RTTNews) - PTC Therapeutics, Inc. (PTCT) reported 2021 total unaudited net revenue of approximately $536 million, representing 41% year-over-year growth. Net product revenue was $429 million, 29% year-over-year growth. The company recorded strong year-over-year growth for the Duchenne muscular dystrophy franchise, with unaudited net product

SOUTH PLAINFIELD, N.J., Jan. 3, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the 40th Annual J.P.

PTC Therapeutics, Inc. (NASDAQ:PTCT) gapped down before the market opened on Thursday . The stock had previously closed at $40.85, but opened at $39.58. PTC Therapeutics shares last traded at $41.26, with a volume of 80 shares. PTCT has been the subject of several research analyst reports. Credit Suisse Group reduced their target price on []

Equities research analysts expect PTC Therapeutics, Inc. (NASDAQ:PTCT) to announce sales of $134.21 million for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for PTC Therapeutics earnings. The lowest sales estimate is $96.34 million and the highest is $162.70 million. PTC Therapeutics posted sales of $118.86 million in the same quarter []

Fisher Asset Management LLC lifted its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) by 9.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 176,156 shares of the biopharmaceutical companys stock after purchasing an additional 15,671 shares during []

Invesco Ltd. grew its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) by 38.6% in the second quarter, Holdings Channel.com reports. The institutional investor owned 39,623 shares of the biopharmaceutical companys stock after buying an additional 11,041 shares during the quarter. Invesco Ltd.s holdings in PTC Therapeutics were worth $1,675,000 at the end of the most recent []

Los Angeles, USA, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Phenylketonuria Pipeline Shows Rapid Progress in Clinical Trials | DelveInsight There are approximately 15+ key companies developing the Phenylketonuria therapies. In the upcoming years, many new products such as CNSA-001/PTC923 (PTC Therapeutics), HMI-102 (Homology Medicines), and SYNB1618 (Synlogic) are also expected to enter the Phenylketonuria market. PTC-923 is expected to be the most promising drug among all the upcoming therapies. DelveInsight''s " Phenylketonuria Pipeline Insight " report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Phenylketonuria pipeline landscapes. It comprises Phenylketonuria pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Phenylketonuria therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Phenylketonuria pipeline products. Some of the key takeaways from the Phenylketonuria Pipeline Report Major companies such as Synlogic, Homology Medicines, PTC therapeutics, Rubius Therapeutics, NestlÃ, BioMarin, SOM Biotech, Evox Therapeutics, Moderna Therapeutics, Orpharma, Generation Bio, Erydel, Janana therapeutics, American gene technologies, Applied Pharma Research and others are developing potential drug candidates to improve the Phenylketonuria treatment scenario.

PTC Therapeutics, Inc. (NASDAQ:PTCT) has earned a consensus recommendation of “Buy” from the twelve research firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and seven have given a buy recommendation to the company. The average 12-month target price […]

SOUTH PLAINFIELD, N.J., Dec. 6, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Evrysdi® (risdiplam) has received multiple awards that recognize it as one of the most innovative therapies of 2021 and for its life-saving impact. The British Pharmacological

Equities research analysts forecast that PTC Therapeutics, Inc. (NASDAQ:PTCT) will report earnings of ($1.98) per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for PTC Therapeutics’ earnings. The lowest EPS estimate is ($2.65) and the highest is ($1.38). PTC Therapeutics reported earnings of ($1.08) per share during the same […]

Metropolitan Life Insurance Co NY increased its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) by 112,452.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,134 shares of the biopharmaceutical companys stock after purchasing an additional 19,117 shares during the quarter. Metropolitan Life Insurance []

PTC Therapeutics (NASDAQ: PTCT) has recently received a number of price target changes and ratings updates: 11/12/2021 PTC Therapeutics was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of []